The price of Revance Therapeutics Inc. (NASDAQ:RVNC) shares last traded on Wall Street fell -2.08% to $18.32.
Based on available information, 13 analysts follow Revance Therapeutics Inc. (NASDAQ:RVNC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $19.00, we find $31.50. Given the previous closing price of $18.71, this indicates a potential upside of 68.36 percent. RVNC stock price is now -16.87% away from the 50-day moving average and -6.00% away from the 200-day moving average. The market capitalization of the company currently stands at $1.52B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 2 rate the stock a hold while 9 rate it a buy. Brokers who have rated the stock have averaged $32.75 as their price target over the next twelve months.
With the price target of $27, Morgan Stanley recently initiated with Equal-Weight rating for Revance Therapeutics Inc. (NASDAQ: RVNC). On September 22, 2022, Goldman recently initiated its ‘Buy’ rating on the stock quoting a target price of $33, while ‘Wells Fargo’ rates the stock as ‘Equal Weight’.
In other news, Moxie Dwight, SVP, GC & Secretary sold 11,000 shares of the company’s stock on Sep 14. The stock was sold for $297,798 at an average price of $27.07. Upon completion of the transaction, the SVP, GC & Secretary now directly owns 31,694 shares in the company, valued at $0.58 million. Insiders disposed of 87,515 shares of company stock worth roughly $1.6 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RVNC stock. A new stake in Revance Therapeutics Inc. shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $19,528,000. JERICHO CAPITAL ASSET MANAGEMENT L.P. invested $13,080,000 in shares of RVNC during the first quarter. In the first quarter, CIBC ASSET MANAGEMENT INC acquired a new stake in Revance Therapeutics Inc. valued at approximately $9,181,000. GHOST TREE CAPITAL, LLC acquired a new stake in RVNC for approximately $7,145,000. TANG CAPITAL MANAGEMENT LLC purchased a new stake in RVNC valued at around $5,267,000 in the second quarter. In total, there are 245 active investors with 89.40% ownership of the company’s stock.
A candlestick chart of Revance Therapeutics Inc. (NASDAQ: RVNC) showed a price of $18.71 on Wednesday morning. During the past 12 months, Revance Therapeutics Inc. has had a low of $11.27 and a high of $30.95. As of last week, the company has a debt-to-equity ratio of 2.67, a current ratio of 5.60, and a quick ratio of 5.30. The fifty day moving average price for RVNC is $22.04 and a two-hundred day moving average price translates $19.49 for the stock.
The latest earnings results from Revance Therapeutics Inc. (NASDAQ: RVNC) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.88, missing analysts’ expectations of -$0.86 by -0.02. This compares to -$1.10 EPS in the same period last year. The company reported revenue of $29.02 million for the quarter, compared to $19.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 46.95 percent. For the current quarter, analysts expect RVNC to generate $27.94M in revenue.
Revance Therapeutics Inc.(RVNC) Company Profile
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
